About Remedium Bio
Remedium Bio is a company based in Needham (United States) founded in 2020 by Frank Luppino. Remedium Bio has raised $15 million across 7 funding rounds from investors including MicroVentures, Guindy Alumni Angels and LifeSpan Vision Ventures. Remedium Bio offers products and services including Prometheus Platform, Gene Therapy for Obesity and T2D, and Gene Therapy for Stroke. Remedium Bio operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Needham, United States
- Founders Frank Luppino
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$15 M (USD)
in 7 rounds
-
Latest Funding Round
$10 M (USD), Series A
Aug 10, 2026
-
Investors
MicroVentures
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Remedium Bio
Remedium Bio offers a comprehensive portfolio of products and services, including Prometheus Platform, Gene Therapy for Obesity and T2D, and Gene Therapy for Stroke.
Adjustable gene therapy for safe delivery of treatments
Single-injection therapy targeting weight loss and diabetes
Regenerative treatment for ischemic stroke recovery
People of Remedium Bio
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Remedium Bio
Remedium Bio has successfully raised a total of $15M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Remedium Bio
Remedium Bio has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include MicroVentures, Guindy Alumni Angels and LifeSpan Vision Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Sherwood Ventures is engaged in management consulting with equity stakes.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Remedium Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Remedium Bio
Investment portfolio details for Remedium Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Remedium Bio
Detailed financials for Remedium Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Remedium Bio Comparisons
Peer comparison for Remedium Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Remedium Bio
Remedium Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
Detailed competitors of Remedium Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Remedium Bio
Complete news archive for Remedium Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Remedium Bio
Remedium Bio was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Remedium Bio is headquartered in Needham, United States. It is registered at Needham, Massachusetts, United States.
Frank Luppino is the current CEO of Remedium Bio. They have also founded this company.
Remedium Bio is a funded company, having raised a total of $15M across 7 funding rounds to date.
Remedium Bio was founded in 2020 and is based in Needham, United States. Gene therapies are developed for a range of diseases, particularly immune and age-related conditions. The pipeline encompasses RMD 1101 for rheumatology, RMD 1202 for endocrinology, RMD 1501 for neurology, and RMD 1201 for Type-1 diabetes. Operations are conducted in the biotechnology sector, with emphasis on therapeutic advancements for these areas.
Remedium Bio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Remedium Bio offers Prometheus Platform, Gene Therapy for Obesity and T2D, and Gene Therapy for Stroke.
Remedium Bio has 10 investors. Key investors include MicroVentures, Guindy Alumni Angels, LifeSpan Vision Ventures, National Science Foundation, and Sherwood Ventures.